SWOG clinical trial number
S1900E

A PHASE II STUDY OF AMG 510 IN PATIENTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (ECOG-ACRIN LUNG-MAP SUB-STUDY)

100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Abbreviated Title
LUNGMAP S1900E: KRAS Targeted Therapy Sub-Study
Status Notes
Effective December 27, 2024 at 12:00 p.m. Pacific Time, sub-study S1900E will be permanently closed to accrual as it has met its protocol-specified accrual goal.

This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Activated
04/02/2021
Closed
12/27/2024

Other Clinical Trials

S2414
SWOG Clinical Trial Number
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
0% Accrual
Accrual
0%
Open
Phase
CTSU/NRG-LU007
SWOG Clinical Trial Number